Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Decreased by Natixis Advisors LLC

Natixis Advisors LLC lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 18.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,545 shares of the specialty pharmaceutical company's stock after selling 4,289 shares during the quarter. Natixis Advisors LLC's holdings in Jazz Pharmaceuticals were worth $2,284,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $25,000. Jones Financial Companies Lllp boosted its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the last quarter. UMB Bank n.a. grew its holdings in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after acquiring an additional 129 shares in the last quarter. Lindbrook Capital LLC increased its position in shares of Jazz Pharmaceuticals by 82.6% in the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock worth $48,000 after purchasing an additional 176 shares during the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in shares of Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock valued at $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Needham & Company LLC reissued a "buy" rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $4.48 during trading hours on Thursday, hitting $126.40. The stock had a trading volume of 1,607,956 shares, compared to its average volume of 711,989. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock's fifty day simple moving average is $132.19 and its 200 day simple moving average is $122.29. The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Patricia Carr sold 1,140 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the transaction, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. This represents a 13.98 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.